Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Intravenous Abatacept in Treatment-Resistant Nephrotic Syndrome (FSGS/Minimal Change)
2015-005450-36Phase 2
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nephrosis and focal segmental glomerulosclerosis (FSGS) comparing Abatacept with Placebo (2 arms). Primary endpoint: Renal response at Day 113.
02
Drugs
abatacept
03
Conditions
nephrosisfocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2015-005450-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005450-36.